Anti-Diabetic Medication Actos Linked To Bladder Cancer

As a result of Actos, a prescription anti-diabetic medication, being linked to reports of bladder cancer, The U.S. Food and Drug Administration has updated the drug's label. The new Actos packaging now warns users that taking the medication for over a year may lead to an increased risk of this form of cancer. 

Actos, also known by its generic name, Pioglitazone, is manufactured by global pharmaceutical company Takeda, and is typically used to treat Type 2 diabetes. This type of diabetes is a condition in which the body does not properly use insulin and as a result cannot control the amount of sugar in the blood. 

In addition to presenting a potential increased risk of bladder cancer, Actos has been associated with the following side effects and symptoms:

  • Development of certain heart conditions
  • Worsening of existing heart conditions
  • Cause of liver disease
  • Possible weight gain
  • Persistent sore throats    
  • Muscle pain
  • Vision problems; blurred vision
  • Yellowing of the eyes
  • Bone fractures
  • Persistent nausea and/or vomiting
  • Abdominal pain

In June 2011, new Actos safety announcement labels were issued by the FDA upon the completion of a thorough study, which began in September 2010, and analyzed the medication's link to bladder cancer risk. At the same time, drug regulators banned the use of Actos in France and Germany. 

According to the FDA, more than 500,000 adverse reactions to anti-diabetic drugs were reported from 2004 to 2009. Within those cases, 138 instances of bladder cancer were reported, with 1/5 of the cancer patients taking Actos.

If you or a loved one have suffered serious side effects as a result of taking Actos, you may be entitled to compensation. Please call our office for a free and confidential consultation.

Trackbacks (0) Links to blogs that reference this article Trackback URL
Comments (0) Read through and enter the discussion with the form at the end
Post A Comment / Question Use this form to add a comment to this entry.

Remember personal info?